KRAS-mutant lung adenocarcinoma subsets exhibit distinct patterns of immune system engagement. KRAS-mutant lung adenocarcinoma subsets exhibit distinct.

Slides:

Advertisements

Similar presentations

Volume 18, Issue 3, Pages (January 2017)

Advertisements

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma Julien Faget, PhD, Caroline Contat, MS, Nadine.

Kenneth G. Geles, Wenyan Zhong, Siobhan K

Volume 20, Issue 13, Pages (September 2017)

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Supplementary Figure 4 a b c d e f

ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

LATS2 is a tumor suppressor in a mouse lumB breast cancer model.

Microarray analysis of phospho-Twist1–responsive genes.

Deletion of Lats1 is phenotypically distinct from Lats2 deletion in PyMT tumors. Deletion of Lats1 is phenotypically distinct from Lats2 deletion in PyMT.

Tregs and APC subsets in TDLNs of patients with cervical cancer.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Volume 18, Issue 3, Pages (January 2017)

Volume 19, Issue 11, Pages (June 2017)

Volume 37, Issue 6, Pages (December 2012)

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.

Th1 and CTL-based immune signature and elevated checkpoint expression in MSI colorectal cancer. Th1 and CTL-based immune signature and elevated checkpoint.

Silencing Ifngr1 in the CMT167 line confers decreased response to IFNγ in vitro and in vivo. Silencing Ifngr1 in the CMT167 line confers decreased response.

The SI-Induced Increase in PA Levels Is Mediated by PbrPLDδ1 in Pollen

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

PMPs survive STZ cytotoxicity and produce larger colonies with a higher yield of insulin+ progeny. PMPs survive STZ cytotoxicity and produce larger colonies.

Extended analysis of differential expression datasets.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

The CREBBP-modulated network is enriched in signaling pathways upregulated in the light zone (LZ). The CREBBP-modulated network is enriched in signaling.

Diaphanous regulates the presynaptic actin cytoskeleton.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Correlation of RSPO expression to LGR5 expansion in gastric cancer.

Antitumor immunity caused by DS-8201a.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

A, PTEN loss signature score in resected SQCLC brain metastases.

Integrated mRNA and microRNA expression and DNA methylation clusters.

CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. A,

DAC treatment activates expression of immunoregulatory genes.

AXL is not expressed in human prostate tumors.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

EN1 expression in breast cancer and clinical outcome.

FILM protein signature predicts poor survival in nontreated stage-IB lung adenocarcinoma. FILM protein signature predicts poor survival in nontreated stage-IB.

Targetable alterations and pathways in TNBCs after NAC

CREBBP loss-of-function results in gene expression repression signature. CREBBP loss-of-function results in gene expression repression signature. A–D,

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

PD-L1 is expressed in breast cancer.

RUNX3 depletion induces cellular senescence and inflammatory cytokine expression in cells undergoing TGFβ-mediated EMT. A, Cells were transfected with.

Activation status of CD8+ T cells.

High-risk neuroblastoma molecular subtypes classification and inference of master regulators. High-risk neuroblastoma molecular subtypes classification.

Stk11/Lkb1 ablation directly promotes primary resistance to PD-L1/PD-1 blockade in immunocompetent murine models of Kras-mutant LUAC. Stk11/Lkb1-proficient/deficient.

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

Validation of NAA's cancer specificity in lung cancer.

G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively.

Distinct subtypes of CAFs are detected in human PDAC

GCS-100 selectively kills KRAS-addicted lung tumors.

EZH2-driven lung cancer as a molecularly distinct entity.

Expression of TGFβ ligands in GBM

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

Identification and characterization of activated integrin pathway module by signal transduction representation (A) and unsupervised hierarchical clustering.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

SCLC initiated from pulmonary neuroendocrine cells metastasizes without upregulating NFIB. A and B, Mouse models of SCLC. Rb1flox/flox;Trp53flox/flox;p130flox/flox;R26mTmG.

KRAS co-mutations are associated with distinct therapeutic vulnerabilities. KRAS co-mutations are associated with distinct therapeutic vulnerabilities.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

Characteristic gene expression patterns distinguish LCH cells from other immune cells present in LCH lesions. Characteristic gene expression patterns distinguish.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

KRAS-mutant lung adenocarcinoma subsets exhibit distinct patterns of immune system engagement. KRAS-mutant lung adenocarcinoma subsets exhibit distinct patterns of immune system engagement. A, IPA identifies several immune-related modules among the top ten upregulated pathways in the KP cluster. B, GSEA reveals prominent enrichment of signatures relating to inflammation, antitumor immunity, and immune tolerance/escape in the KP subgroup. C, heatmap representation of relative mRNA expression levels of selected targetable immune checkpoint mediator/effector molecules. D, expression of CD274 (PD-L1) mRNA in KRAS-mutant lung adenocarcinoma subsets. ANOVA is used for statistical comparison between the three groups. E, comparison of PD-L1 H-score between KL and KP tumors in a tissue microarray from PROSPECT. A single confirmed triple-mutant tumor (KRAS;TP53;LKB1) in this cohort is excluded from the analysis. Wilcoxon rank-sum test is used for statistical comparison. Asterisk denotes statistical significance at P ≤ 0.05. Error bars, SD of the mean. H-score, histoscore. F, representative images of CD274 immunostaining in lung adenocarcinomas from the KL (KL1/KL2) and KP (KP1/KP2) clusters. Scale bar, 200 μm. Ferdinandos Skoulidis et al. Cancer Discovery 2015;5:860-877 ©2015 by American Association for Cancer Research